Core Viewpoint - WuXi Biologics (02269.HK) shows a recovering stock price trend, indicating market optimism for its future performance [1][11]. Price Performance - The stock price closed at HKD 24.95 on June 2, 2025, with a stable trading day and a cumulative volatility of 10.8% over the past week, suggesting potential for a breakthrough [1]. - In just two days, the stock price increased by 6.62%, positively impacting related derivative products, with notable performances from JPMorgan and UBS leveraged products, which rose by 28% and 20% respectively [1][7]. Technical Analysis - Support levels for WuXi Biologics are identified at HKD 22.9 and HKD 23.5, confirming bottom support as the stock stabilizes above these levels [3]. - Resistance levels are at HKD 25.8 and HKD 26.8; a breakthrough of the first resistance could lead to a new upward trend [3]. - The probability of an upward movement is assessed at 53%, indicating a neutral to bullish sentiment [3]. Technical Signals - A strong buy signal is indicated by 17 technical signals supporting a bullish outlook, including moving averages and mid-term trend indicators [6]. - The MACD and Ichimoku indicators also provide buy signals, reinforcing expectations for trend continuation [6]. Derivative Products - For bullish investors, the Bank of China call option (15841) offers a stable choice with a leverage of 3.3 times and an exercise price of HKD 24.88, minimizing time decay impact [7]. - For higher leverage, the Morley call option (14687) provides a leverage of 1.9 times, suitable for short-term trading [7]. - Investors interested in bull certificates may consider JPMorgan's product (57118), which offers a leverage of 5.3 times with a recovery price of HKD 22 [7]. Market Outlook - The overall market sentiment is positive, with expectations for further upward movement if the stock can effectively break through the key resistance level of HKD 25.8 [11]. - The stock is currently in a stabilizing phase, and any short-term fluctuations should be viewed as a healthy consolidation process for future gains [11].

新华财经罗马6月4日电（记者高婧妍）中国潮流玩具品牌泡泡玛特继在米兰Corso Buenos Aires大街开 设意大利首家门店近一年后，日前在米兰市中心开设临时快闪店，进一步扩大其在意大利市场的影响 力。 据意大利《Il Giorno》日报报道，米兰快闪店的开业引发数百人排队，甚至有顾客从2日晚间开始排 队，只为抢购Labubu系列玩具。 泡泡玛特近年来在全球市场持续扩张。尽管欧洲业务在其全球版图中占比不大，但增长十分迅猛。意大 利TG24天空电视台称，泡泡玛特已跃升为全球玩具与娱乐行业的领导品牌。 （文章来源：新华财经） 自2024年底以来，泡泡玛特推出的Labubu及其他盲盒产品在意大利市场迅速走红，引发大批粉丝排队 抢购。本次开设的快闪店回应了广大消费者对泡泡玛特人气产品的持续热情。 报道还称，据泡泡玛特南欧地区销售负责人Marco Ardizzone透露，品牌预计于2025年7月底在意大利开 设第二家官方门店。该举措被认为是公司巩固其欧洲市场布局、满足日益增长的本地消费者需求的重要 一步。 据意大利TG24天空电视台网站报道，快闪店选址在当地知名百货商场Rinascente地下一层，售卖泡泡玛 特各 ...

每经记者｜金喆 林姿辰 每经编辑｜陈俊杰 6月4日，康方生物方面向《每日经济新闻》记者表示，经调查核实，对于患者李某美使用的临床研究药 物，公司重庆销售人员通过伪造研究立项文件及医院伦理批件等材料，以研究者发起的药品上市后临床 研究的名义，从公司骗取了若干药物，并无偿给予患者李某美使用。公司从未向患者李某美收取任何费 用，公司经办销售人员亦未收取患者李某美的任何费用。 记者了解到，为规范临床试验，国家药品监督管理局和国家卫生健康委员会对临床试验药物有非常严格 的管理要求。国内某顶级肿瘤医院负责临床试验的医务人员告诉记者，他们有专人管理和记录用于临床 试验的药物，临床研究助理会负责清点药品数量、进行回收登记和双人核对。 康方生物否认向患者销售临床研究用药 卡度尼利单抗注射液是康方生物的PD-1单抗，在2022年6月获得国家药品监督管理局批准上市，用于治 疗复发或转移性宫颈癌。 从去年4月到今年2月，李某美每隔21天注射一次卡度尼利单抗注射液，每次5支，共计用药十四五次， 约有70瓶。 康方生物方面对记者表示，经公司内部自查，并向相关DTP（直接面向患者）药房以及患者李某美本人 核实：2024年4至5月期间，患者 ...

美股开盘，三大股指小幅高开。纳斯达克中国金龙指数涨0.77%，涨幅居前的个股为：再鼎医药 (ZLAB.O)涨9.4%、名创优品(MNSO.N)涨4.7%。 ...

Core Insights - The Chinese toy brand Blokus made its debut at the influential Latin American pop culture event "CCXPMéxico2025," showcasing its products to a global audience of anime, gaming, film, and toy enthusiasts [1] - Blokus is recognized as a leading brand in the building block toy category in China, featuring well-known global IPs such as Neon Genesis Evangelion, Hatsune Miku, Marvel, Saint Seiya, Transformers, Ultraman, Naruto, and Heroes Infinite [1] - The participation in "CCXPMéxico2025" marks a significant milestone in Blokus's globalization strategy, following its previous expansions into Chile, Peru, Panama, and Brazil [1] Product and Market Strategy - Blokus focused on products aimed at fans aged 16 and above, aligning with the main audience of the event [1] - The company has established a unique innovation and research system, holding over 500 patents, which supports its diverse product offerings [1] - Blokus has developed six classic series, including Hero5, Hero8, Hero10, Champion, Legend, and Fantastic, with a total of over 600 SKUs, characterized by high IP fidelity, ease of assembly, strong playability, and affordability [1] Global Expansion - Under the "all demographics, all price points, globalization" strategy, Blokus has achieved breakthroughs in multiple global markets, including Southeast Asia, Europe, North America, and Latin America [2] - The company aims to deepen its presence in the Latin American market by providing high-quality products and unique brand culture, enhancing the building experience for global players [2]

泡泡玛特成了"年轻人的茅台"，随着泡泡玛特大涨，不少曾经重仓持有贵州茅台的基金经理，开始"转 战"泡泡玛特。 与此同时，新消费领域也成为基金经理追逐的对象，涉及潮玩、体验经济、特色文旅、医美、宠物经 济、美妆个护等领域。 Wind数据显示，年内押注新消费的权益类基金今年以来最高回报率超60%。 受访基金经理认为，当前不少新消费类公司的估值已不便宜，短期内股价有调整的风险。但从中长期角 度看，很多新消费公司仍处于成长的中早期阶段，未来仍有较大的成长空间。 富国消费精选30基金经理周文波表示，关于"新消费"有很多不同的理解与看法，新消费的核心，在于这 些公司适应了经济环境变化和消费者行为转型，聚焦于新兴需求、创新模式及全球化拓展等。这些公司 的重要特征是拥有清晰的成长逻辑，业绩保持较快增长，且具有较好的发展前景。 比如潮玩、体验经济、特色文旅、医美、宠物经济等"悦己型"消费等，能给消费者带来开心、快乐。 事实上，今年以来，新消费和传统消费的投资回报差别很大。 根据Wind数据，截至今日发稿，年内申万宏源消费指数上涨0.82%。 其中，代表传统消费的中证白酒指数下跌9.83%、中证家电龙头指数下跌2.44%。 而代 ...

智通财经记者 | 唐卓雅 智通财经编辑 | 许悦 另外，阿美替尼联合化疗用于EGFR敏感突变的局部晚期或转移性非小细胞肺癌一线治疗的上市许可申 请已于2024年11月获国家药监局受理。 EGFR-TKI靶点同PD-1类似，以"内卷"出名。截至2025年3月19日，国内已有7款第三代EGFR-TKI产品 上市，除了翰森制药的阿美替尼外，还有奥希替尼（阿斯利康）、伏美替尼（艾力斯）、贝福替尼（贝 达药业/益方生物）、瑞齐替尼（倍而达/石药集团）、瑞厄替尼（圣和药业）以及利厄替尼（奥赛康药 业/信达生物）。 6月4日，翰森制药宣布，其创新药甲磺酸阿美替尼片（英国商品名：Aumseqa®）获英国药品与保健品 监管局（MHRA）批准上市，作为单药治疗适用于成人局部晚期或转移性非小细胞肺癌（NSCLC）且 具有激活的表皮生长因子受体（EGFR）突变的患者的一线治疗，以及成人局部晚期或转移性EGFR T790M突变阳性非小细胞肺癌患者的治疗。 甲磺酸阿美替尼片（以下简称：阿美替尼）成为翰森制药首个获准进入海外市场的创新药，同时也是首 个海外上市的中国原研EGFR-TKI（表皮生长因子受体酪氨酸激酶抑制剂）。 6月4日，智通 ...

Market Overview - On June 4, the Hang Seng Index rose by 0.60%, with southbound trading totaling HKD 1,063.30 billion, comprising buy transactions of HKD 549.23 billion and sell transactions of HKD 514.07 billion, resulting in a net buy of HKD 35.16 billion [2][4] Active Stocks - The most actively traded stock by southbound funds was Xiaomi Group-W, with a total transaction amount of HKD 54.40 billion. Meituan-W and Alibaba-W followed with transaction amounts of HKD 47.39 billion and HKD 43.75 billion, respectively [2][3] - In terms of net buying, Meituan-W led with a net buy of HKD 14.14 billion, followed by Alibaba-W with HKD 6.20 billion and BYD Company with HKD 3.94 billion [2][3] Net Selling Stocks - Tencent Holdings experienced the highest net selling amount at HKD 14.36 billion, despite its stock price increasing by 1.39%. Xiaomi Group-W and SMIC faced net selling amounts of HKD 13.75 billion and HKD 1.35 billion, respectively [2][4] Continuous Net Buying - Three stocks have seen continuous net buying for more than three days, with Meituan-W leading at 13 days, followed by CSPC Pharmaceutical Group at 4 days and Alibaba-W at 3 days. The total net buying amounts during this period were HKD 144.10 billion for Meituan-W, HKD 22.53 billion for CSPC, and HKD 16.49 billion for Alibaba-W [3]

巨子、华熙商战迎来最新进展。 二、针对可复美重组胶原蛋白肌御修护次抛精华液(可复美胶原棒2.0)，检测结果如下： 我们在A检测机构也采用LC-MS/MS(液相色谱-串联质谱法)进行全序列定性检测分析，确认产品中含有 重组胶原蛋白。 同时为了验证重组胶原蛋白含量的自检数据，我们将该产品送至D检测机构采用双缩脲法进行交叉检 验，重组胶原蛋白含量同样大于0.1%。 以上为本次检测结果。 今日，巨子生物在其官方账号公布了最新的检测结果，同时对1.0产品多平台下架给出解释。 巨子生物在声明中提到： 一、针对可复美Human-like重组胶原蛋白肌御修护次抛精华(可复美胶原棒1.0)，检测结果如下： 首先我们在A检测机构采用LC-MS/MS(液相色谱-串联质谱法)进行全序列定性检测分析，确认产品中含 有重组胶原蛋白。 同时，我们在B检测机构对随机抽取的三个批次产品进行双缩脲法检测，结果显示，三个批次产品的重 组胶原蛋白含量均大于0.1%。 我们又将上述送检的三个批次中的其中一个批次产品送至C检测机构用双缩脲法进行交叉检验，结果显 示，本批次产品的重组胶原蛋白含量同样大于0.1%。 关于聚谷氨酸钠是否会影响双缩脲法的检测结 ...

Core Viewpoint - Jiangtian Technology's reliance on major clients, particularly Nongfu Spring, has raised concerns about its growth sustainability and IPO prospects, as recent financial performance shows signs of decline despite previous growth [2][6][7] Company Overview - Jiangtian Technology specializes in the research, production, and sales of label printing products, including film and paper-based self-adhesive labels, widely used in daily consumer sectors such as beverages, personal care, and food [6] - The company has experienced revenue growth from 347 million yuan in 2021 to 538 million yuan in 2024, with a compound annual growth rate (CAGR) of 15.47%, and net profit growth from 61 million yuan to 102 million yuan, with a CAGR of 18.69% [6] Recent Financial Performance - As of Q1 2025, Jiangtian Technology reported revenue of 134 million yuan, a slight increase of 2.12% year-on-year, but net profit decreased by 9.66% to 26 million yuan, marking the first negative growth in five years [6] - The company's heavy dependence on major clients has begun to show risks, particularly as Nongfu Spring's revenue growth slowed to 0.54% in 2024, the lowest in five years [7] Challenges and Risks - Jiangtian Technology faces challenges such as reduced order amounts from major clients like Yili Group and declining prices for core products, which may impact overall performance [7] - The company is also dealing with internal control risks related to shareholding structures and related party transactions, as well as insufficient pricing power for its products, which could hinder its IPO process [7]